Eli Lilly (NYSE:LLY) announced a collaboration with Repertoire Immune Medicines to develop next generation autoimmune ...

In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...

The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...

PCRF is proud to support Oncoheroes because our missions are deeply aligned. We believe that children deserve access to ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...